The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement

European Journal of Clinical Pharmacology

Volumn 67, Issue 6, 2011, Pages 581-590

  Zhong, Shi Long ^a   Liu, Yuan ^a   Yu, Xi Yong ^a   Xu, Dan ^a   Tan, Hong Hong ^a   Lin, Qiu Xiong ^a   Yang, Min ^a   Lao, Hai Yan ^a   Lin, Shu Guang ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

CYP2C9; Drug interaction; Initial response; VKORC1; Warfarin

Indexed keywords

AMIODARONE; AMLODIPINE; AZITHROMYCIN; CIPROFLOXACIN; CLAVULANIC ACID; DILTIAZEM; FLUCONAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; RIBAVIRIN; SIMVASTATIN; SULFAMETHOXAZOLE; WARFARIN;

ADULT; ALLELE; ARTICLE; CHINESE; CYP2C9 GENE; CYP3A4 GENE; DRUG RESPONSE; FEMALE; GENE; GGCX GENE; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STX4A GENE; VKORC1 GENE;

ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIAC VALVE ANNULOPLASTY; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HAPLOTYPES; HEART VALVES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; WARFARIN;

EID: 79959699568     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-0995-6     Document Type: Article

References (29)

1. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326-331
2. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF (1996) Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24:422-428
3. Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, Baillie TA, Tang W (2001) In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10- hydroxywarfarin. Drug Metab Dispos 29:877-886
4. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye- Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008 (Pubitemid 351347099)
5. Nishiyama A, Kim-Mitsuyama S (2010) New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system. J Pharmacol Sci 113:289-291
6. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925-3930
7. Kotirum S, Chaiyakunapruk N, Jampachaisri K, Wattanasombat S, Rojnuckarin P (2007) Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy. Pharmacoepidemiol Drug Saf 16:216-222 (Pubitemid 46291173)
8. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F (2006) The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 4:1422-1424
9. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L (2010) Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 37:3-24
10. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538 (Pubitemid 28270907)
11. Stevenson PH (1937) Height-weight-surface formula for the estimation of surface area in Chinese subjects. Chin J Physiol 3:327-330
12. Dorn GW Jr (2010) Therapeutic potential of microRNAs in heart failure. Curr Cardiol Rep 12:209-215
13. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095-1106 (Pubitemid 40720733)
14. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, Wang HH, Yao A, Chen YT, Hsu CN (2006) FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 34:W635-W641 (Pubitemid 44529848)
15. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M, Tai S (2008) Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 396:76-79
16. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120:181-186 (Pubitemid 46754413)
17. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236-239 (Pubitemid 23069000)
18. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751 (Pubitemid 41430097)
19. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23-34 (Pubitemid 46421137)
20. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433
21. Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167:1414-1419 (Pubitemid 47052441)
22. Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF (2003) Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 31:1043-1048 (Pubitemid 36975675)
23. Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM (2010) Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol doi:10.1177/0091270010370588
24. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84:581-588
25. Mootha VV, Schluter ML, Das A (2002) Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol 120:94-95 (Pubitemid 34721371)
26. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M (1988) The incidence, magnitude, and time course of the amiodaronewarfarin interaction. Arch Intern Med 148:1779-1781
27. Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, Bank H (1985) Mechanism of warfarin potentiation by amiodarone: dose- and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 28:257-261 (Pubitemid 15085149)
28. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V (2006) The influence of cotreatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 62:291-296
29. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S (2010) Fibrate/statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 123:151-157